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Background: Tumor necrosis factor-alpha inhibitors are widely used agents in the treatment of immune disorders
such as rheumatoid arthritis and inflammatory bowel disease. Despite their anti-inflammatory action, paradoxical
drug-induced inflammatory events have been occasionally associated with the use of infliximab, etanercept, and
in a lesser extent adalimumab. However, eye involvement is uncommon and anterior uveitis is the only reported
ocular adverse manifestation. It can be induced by etanercept, but has also been described during adalimumab
therapy. We present here the first report of recurrent peripheral corneal infiltrates following subcutaneous injections of
adalimumab.
Case presentation: A 34 year-old Caucasian woman with Crohn’s disease presented to the emergency department
with bilateral red eyes and discomfort 36 hours after she received her bimonthly dose of subcutaneous adalimumab.
Examination revealed bilateral peripheral corneal infiltrates with characteristic features of immune infiltrates. Symptoms
and infiltrates regressed after topical corticosteroid therapy, but recurred after each adalimumab injection over the
following weeks.
Conclusion: Paradoxical immune reactions associated with tumor necrosis factor-alpha inhibitors may result either from
hypersensitivity mechanisms, or from immune-complex deposition via anti-adalimumab antibodies. Both mechanisms
could explain this newly described manifestation. Care should be taken to search for corneal infiltrates in the event of
red eye symptoms during adalimumab therapy since they respond to topical corticosteroids and do not necessarily
prompt the discontinuation of the immunosuppressive therapy.
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Crohn's diseaseBackground
Adalimumab is a recombinant monoclonal antibody
that inhibits tumor necrosis factor alpha (TNF-α), a
pro-inflammatory cytokine. It is commonly employed
for several immune-mediated disorders, including in-
flammatory bowel disease, ankylosing spondylitis and
rheumatoid arthritis, with favorable safety reports [1, 2].
Yet, adverse events are progressively identified. Their
diagnosis can be challenging since they often share
features with the underlying inflammatory condition
for which the drug is prescribed. The most common
adverse manifestations include dermatitis, fever, interstitial* Correspondence: drbourges@gmail.com
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infrequent. To date, anterior uveitis is the only ocular
adverse event registered in the literature [3]. In this report,
we describe recurrent and bilateral peripheral corneal in-
filtrates caused by subcutaneous injections of adalimumab.
To the best of our knowledge, this is the first report of
adalimumab-induced corneal infiltrates.
Case presentation
A 34 year-old Caucasian woman with Crohn’s disease
presented to the eye emergency department at our insti-
tution with bilateral red eyes and discomfort. She had
been wearing soft daily-wear contact lenses with
monthly replacement schedule for the past 10 years. She
had stopped wearing them 3 months before her visit as
a consequence of fluctuating dry eye symptoms. She also
reported a recent episode of interface dermatitis on herrticle distributed under the terms of the Creative Commons Attribution
es/by/4.0), which permits unrestricted use, distribution, and reproduction in
properly credited. The Creative Commons Public Domain Dedication waiver
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She developed HLA-B27-negative ileal Crohn's disease
at age 18, and required two intestinal resections at age
20 and 25 for stricturing disease. Thereafter, inflamma-
tion had been satisfactorily controlled by oral azathio-
prine. At the age of 30, 4 years before her visit to our
emergency department, recurrence of clinical symptoms
led to a switch from oral azathioprine to subcutaneous
adalimumab. She had since been receiving 40 mg of
subcutaneous adalimumab every 2 weeks.
Prior to the current episode, the patient had been evalu-
ated biennially for 10 years by her attending ophthalmolo-
gist in the context of contact lens use. At each visit, she had
been screened for ocular signs related to her inflammatory
bowel disease. Her corneal status was unremarkable at all
examinations. In particular, the patient did not have any
history of meibomian gland disease or marginal keratitis.
Ocular symptoms occurred 36 hours following the last
adalimumab administration and were more intense in
her left eye. The patient did not report any loss of vision.
In addition to diffuse conjunctival hyperemia and peri-
limbal injection, slit-lamp examination of her left eye re-
vealed a white-grayish anterior stromal infiltrate near
the inferior corneal margin, with a diameter of 0.3 mm
(Fig. 1: a, b, white arrow), and a string of smaller lesions
along the superior margin (Fig. 1: c, d, black arrows).
We observed a single small lesion in her right eye, lo-
cated along the superior nasal limbus. All signs shared
characteristics of immune infiltrates: a hazy fluorescein
stain with intact epithelium, a clear margin between infil-
trate and limbus, and subtle corneal neovascularization.
The anterior stromal localization of the lesions was visible
on slit-lamp biomicroscopy (Additional file 1: Figure
S1). Symptoms improved and infiltrates cleared withFig. 1 Peripheral corneal infiltrates secondary to systemic adalimumab
for Crohn’s disease. a. Left eye of a 34 year-old female patient
showing a grayish infiltrate near the inferior corneal margin
(white arrow) observed 2 days after subcutaneous administration
of adalimumab. b. Magnified view of the inferior infiltrate (white
arrow) showing subtle corneal vascularization. c and d. String
of smaller infiltrates along the superior corneal margin (black arrows).
e. Regression of infiltrates after one week of topical dexamethasone T.I.D.topical dexamethasone T.I.D (Fig. 1: e). Two weeks
later, 24 hours after the next injection of adalimumab,
the patient returned with recurrent symptoms. Clinical
findings were identical to the first examination in both
eyes and again disappeared with topical dexamethasone
(Additional file 2: Figure S2 and Additional file 3:
Figure S3). After a third episode that was managed in
the same way, and at the patient’s request, sporadic
ocular symptoms were considered acceptable with
regard to the control of bowel inflammation, and adali-
mumab therapy was not discontinued. For the treat-
ment of the few recurrences that occurred over the
following months, dexamethasone was successfully re-
placed by rimexolone to reduce the risk of ocular
hypertension. Two months after the first visit, trough
serum adalimumab was 7.4 μg/mL, within therapeutic
range (1.9 to 8.3 μg/mL) [4].
Discussion
The features and timing of these recurrences strongly point
to adalimumab injections as their causative factor. To the
best of our knowledge, there is no previous report of per-
ipheral corneal inflammation secondary to adalimumab.
The infiltrates could have been a manifestation of the
inflammatory bowel disease itself. Ocular manifestations
during Crohn’s disease indeed include scleritis, episcler-
itis, uveitis and less frequently peripheral corneal infil-
trates, that may complicate sceritis [5, 6]. However,
scleritis was absent in this case, and Crohn’s disease was
quiescent. In fact, the residual serum level of adalimu-
mab fell within therapeutic range [4], indicating efficient
disease control.
Soft contact lens wear is unlikely to be the source of
the peripheral infiltrates in this patient, since they had
been discontinued 3 months before the onset of eye red-
ness and discomfort. Intact corneal epithelium over the
infiltrates and efficient control by steroids also rule out
infectious keratitis. The absence of eyelid inflammation
and the timing of recurrences do not support the hy-
potheses of meibomian gland disease, marginal keratitis
or phlyctenulosis.
Ironically, TNF-α inhibitors are known to generate
adverse inflammatory reactions despite their immuno-
suppressive action. Among them, adalimumab induces
3.5 % of hypersensitivity events, the lowest rate within
this therapeutic class [7]. Cutaneous manifestations are
the most frequent. They include type I hypersensitivity
reactions at injection sites [8], paradoxical inflamma-
tion leading to “psoriasiform” lesions [9] and various
types of dermatitis including interface dermatitis [10],
as developed by our patient. Some reports also point to
adalimumab as the causative agent in drug-induced
interstitial pneumonia [11, 12], fever [13] or vasculitis
[14, 15]. Yet, ocular adverse events have been rarely
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manifestation is acute anterior uveitis [3].
Remarkably, in a recent United States-based registry ana-
lysis of uveitis induced by TNF-α inhibitors, adalimumab
accounted for only 3 % of cases, far less than infliximab
(24 %) and etanercept (73 %) [3]. Scleritis has also been de-
scribed after etanercept [16], but not after adalimumab or
infliximab. However, except for etanercept these agents are
considered safe enough for the treatment of refractory in-
flammatory eye disease, including peripheral ulcerative
keratitis [17], scleritis [18] and uveitis [19, 20].
Regarding its pathogenic mechanism, the formation
of peripheral corneal infiltrates usually requires either
immune-complex deposition or type III hypersensitivity
[21]. In this patient, the presence of anti-adalimumab anti-
bodies was very unlikely, since they would have been asso-
ciated with low drug serum levels and treatment failure due
to the neutralization of adalimumab molecules [22]. For
this reason, laboratory testing was technically not feasible
because the high residual adalimumab level would have
neutralized any circulating anti-adalimumab antibodies.Conclusion
In this report, the patient developed symptomatic, recur-
rent corneal peripheral infiltrates after repeated subcuta-
neous administration of adalimumab, a TNF-α inhibitor.
These infiltrates resulted either from an immune reac-
tion to adalimumab, or from a paradoxical exacerbation
of Crohn’s disease following adalimumab injections.
Given the growing number of individuals under TNF-α
inhibitor therapy, sterile corneal infiltrates should be
meticulously looked for in the event of red eye symp-
toms. They respond to topical corticosteroid therapy
without discontinuation of adalimumab.Consent
Written informed consent was obtained from the patient
for publication of this Case report and any accompanying
images. A copy of the written consent is available for
review by the Editor of this journal.Additional files
Additional file 1: Figure S1. Localization of adalimumab-induced
peripheral infiltrates in the anterior stroma. A. Magnified corneal photograph
of the right eye showing a peripheral infiltrate near the superior nasal
limbus and associated neovascularization (arrow). B. Magnified slit-lamp
biomicroscopy showing the anterior stromal localization of the infiltrate
(arrow).
Additional file 2: Figure S2. Recurrence of the peripheral corneal
infiltrates in the right eye following adalimumab subcutaneous injection.
A. and B. Corneal photographs and magnified area of the superior nasal
cornea after resolution of the first episode, showing a fine residual
opacity and persistent neovascularization. C and D. Corneal photographs
and magnified area of the same region after recurrence of symptoms3 days after the next adalimumab injection, showing a recurrence of the
peripheral infiltrate.
Additional file 3: Figure S3. Recurrence of the peripheral corneal
infiltrates in the left eye following adalimumab subcutaneous injection.
A. Corneal photograph of the left eye, showing the absence of peripheral
lesions after resolution of the first episode. B and C. Magnified areas in
the superior and inferior temporal peri-limbal regions, after resolution of
the first episode. D and E. Magnified areas of the same regions after a
new onset of symptoms 2 days after the subsequent adalimumab
subcutaneous injection, showing recurrent peripheral infiltrates (arrows).
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